Soley Therapeutics has secured $200 million in series C funds, which the artificial-intelligence-enabled biotech plans to use ...
AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting ...
Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...
Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT. The impact of the use of hypomethylating agents ...
Socioeconomic factors, particularly education level, significantly impact access to allo-HCT for AML patients, with lower education reducing transplant likelihood by 30%. Reliance on government ...
A new study led by Fred Hutch Cancer Center looked at zip codes to assess socioeconomic status and access to bone marrow transplants SAN DIEGO, Calif. — Dec. 8, 2024 — Patients with acute myeloid ...
AB Science SA (Euronext - FR0010557264 - AB) today announced the approval of the third of four stages of the Phase I/II study (AB18001) with the compound AB8939 in adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback